Paul Richardson, MD, Dana-Farber Cancer Institute
Articles by Paul Richardson, MD, Dana-Farber Cancer Institute
ASH Takeaways and Future Directions for Multiple Myeloma
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management.
Sequencing BCMA-Targeted Agents in RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM.
Non-BCMA Specific Targets in RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM.
Investigational BCMA Targets in RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM.
Targeting BCMA and CAR T Therapy in RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM.
Emerging Novel Agents in RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM.
Using PI-based Combinations in RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.
Role of IMiD-based Strategies for RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
Approaching Treatment of RRMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
Future of MRD Assessment in NDMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
ASH Updates on Transplant in NDMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
Individualized Induction Therapy for NDMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
Approaching Early Treatment of High-Risk SMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
Role of Therapeutic Intervention in SMM
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
Overview of Smoldering Multiple Myeloma
ByPaul Richardson, MD, Dana-Farber Cancer Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center,David Siegel, MD, PhD, Hackensack Meridian Health,Saad Z. Usmani, MD, Atrium Health 
Role of Therapeutic Intervention in SMM
ASH Updates on Transplant in NDMM
RRMM: INN Melphalan Flufenamide/DEX and Extramedullary Disease
Targeting BCMA and CAR T Therapy in RRMM
RRMM & High-Risk Cytogenetics: INN Melphalan Flufenamide/DEX
INN Melphalan Flufenamide in Triple-Class Refractory/Relapsed MM